Poor infection control, not fluoroquinolones, likely to be primary cause of Clostridium difficile-associated diarrhea outbreaks in Quebec [2]

Clinical Infectious Diseases

Volumn 42, Issue 5, 2006, Pages 725-727

  Weiss, Karl ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; LEVOFLOXACIN; MACROLIDE; OFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; CANADA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA; DIARRHEA; DRUG USE; EPIDEMIC; GOVERNMENT REGULATION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; LETTER; NONHUMAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 33144460610     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/500268     Document Type: Letter

References (13)

1. Pépin J, Sheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254-60.
2. Eggertson L. Quebec puts up 20 million dollars for C. difficile fight. CMAJ 2005; 172:622.
3. Louie T, Meddings J. Clostridium difficile infection in hospitals: risk factors and responses. CMAJ 2004; 171:45-6.
4. Institut National de Santé Publique du Québec. Surveillance des diarrhées associées à Clostridium difficile au Québec. Available at http://www.inspq.qc.ca/publications/. Accessed 30 November 2005.
5. Weiss K, Bergeron L, Bernatchez H, Goyette M. Clostridium difficile associated diarrhea (CDAD) and antibiotics consumption in an outbreak setting: is there a link [abstract K-1271/366]? In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2005.
6. Oldfield EC 3rd. Clostridium difficile-associated diarrhea: risk factors, diagnostic methods, and treatment. Rev Gastroenterol Disord 2004; 4:186-95.
7. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004; 38:640-5.
8. Zhanel GG, Walkty A, Vercaigne L. The new fluoroquinolones: a critical review. Can J Infect Dis 1999; 10:207-38.
9. Pépin J, Valiquette L, Alary M-E, Villemure P, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171:466-72.
10. Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159:2562-72.
11. Mandell LA, Bartlett JG, Dowell SF, et al. Infectious Diseases Society of America: update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-33.
12. Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000; 31:383-421.
13. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37:997-1005.